Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+0,36%
1 096,72
+3,98
+0,36%
—1 092,741 095,951 103,321 094,72——
SIXC
Communications
SIXC
Communications
SIXC
-0,33%
611,32
-2,04
-0,33%
—613,36613,36613,36609,50——
SIXE
Energy
SIXE
Energy
SIXE
-0,45%
1 171,54
-5,25
-0,45%
—1 176,791 176,521 182,251 166,69——
SIXI
Industrials
SIXI
Industrials
SIXI
-0,45%
1 747,63
-7,91
-0,45%
—1 755,541 759,231 766,301 746,04——
SIXM
Financials
SIXM
Financials
SIXM
-0,58%
631,49
-3,66
-0,58%
—635,15635,20636,89630,09——
SIXR
Staples
SIXR
Staples
SIXR
+0,23%
849,94
+1,93
+0,23%
—848,01852,52855,78849,58——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+0,09%
218,06
+0,20
+0,09%
—217,86217,86219,52217,86——
SIXT
Technology
SIXT
Technology
SIXT
+3,47%
3 536,03
+118,68
+3,47%
—3 417,353 452,773 536,033 450,39——
SIXU
Utilities
SIXU
Utilities
SIXU
-0,91%
905,07
-8,29
-0,91%
—913,36915,10920,43904,57——
SIXV
Health care
SIXV
Health care
SIXV
-0,86%
1 449,86
-12,52
-0,86%
—1 462,381 461,131 464,531 446,02——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0,30%
2 430,47
+7,33
+0,30%
—2 423,142 428,712 448,692 424,63——
LGND:NASDAQ
Ligand Pharmaceuticals Inc
USD 221,41
+5,27%
(+11,08) 1D
8 Mei, 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LGND...
Open
USD 212,20
High
USD 223,78
Low
USD 206,02
Mkt. cap
4,44 mjd
Avg. vol.
233,67 k
Volume
249,98 k
P/E ratio
36,10
52-wk high
USD 247,38
52-wk low
USD 98,89
EPS
USD 6,13
Beta
1,12
Shares outstanding
20,04 m
No. of employees
47
News stories
From sources across the web
Profile
Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol. The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments. Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020. Wikipedia
About Ligand Pharmaceuticals Inc
CEO-
Employees47
FoundedSep. 1987
HeadquartersJupiter, Florida, Verenigde State van Amerika
SectorPharmaceutical industry
Websiteligand.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun. 2025
Sep. 2025
Des. 2025
Mrt. 2026
Revenue
47,63 m
115,46 m
59,67 m
51,72 m
Cost of goods sold
9,47 m
24,82 m
6,50 m
3,27 m
Cost of revenue
9,47 m
24,82 m
6,50 m
3,27 m
Research and development expenses
-
-
-
2,15 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
20,18 m
28,45 m
25,03 m
20,84 m
Operating expense
28,43 m
36,54 m
33,12 m
31,08 m
Total operating expenses
37,91 m
61,36 m
39,63 m
34,35 m
Operating income
9,72 m
54,10 m
20,04 m
17,37 m
Other non operating income
96,00 k
390,00 k
1,48 m
-1,18 m
EBT including unusual items
11,22 m
141,14 m
56,78 m
-24,26 m
EBT excluding unusual items
10,28 m
57,45 m
116,80 m
21,10 m
Income tax expense
6,38 m
23,86 m
12,00 m
-10,91 m
Effective tax rate
56,81%
16,91%
21,13%
44,99%
Other operating expenses
-
-
-
-
Net income
4,85 m
117,27 m
44,78 m
-13,34 m
Net profit margin
10,18%
101,57%
75,06%
-25,80%
Earnings per share
1,60
3,09
2,02
1,63
Interest and investment income
1,62 m
3,87 m
6,39 m
4,91 m
Interest expense
-1,15 m
-910,00 k
-1,78 m
-
Net interest expenses
468,00 k
2,96 m
4,61 m
4,91 m
Depreciation and amortization charges
-
-
-
-
EBITDA
17,82 m
63,26 m
28,25 m
25,81 m
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer